Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

PURPOSE: The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell proliferation and survival. Everolimus is an oral agent targeting raptor mTOR (mTORC1). The trial's goal was to determine the antitumor activity and safety of single-agent e...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Ghobrial, Irene M., Gertz, Morie, LaPlant, Betsy, Camoriano, John, Hayman, Suzanne, Lacy, Martha, Chuma, Stacey, Harris, Brianna, Leduc, Renee, Rourke, Meghan, Ansell, Stephen M., DeAngelo, Daniel, Dispenzieri, Angela, Bergsagel, Leif, Reeder, Craig, Anderson, Kenneth C., Richardson, Paul G., Treon, Steven P., Witzig, Thomas E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2010
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834498/
https://ncbi.nlm.nih.gov/pubmed/20142598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.0994
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller